This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Biotin-dependent carboxylase deficiency, Multiple carboxylase deficiency바이오틴-의존카복실레이스결핍

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D81.8 (other specified combined immunodeficiencies) | OMIM: 253270 (HCS deficiency), 253150 (BTD deficiency) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsBiotin-dependent carboxylase deficiency, Multiple carboxylase deficiency (MCD), holocarboxylase synthetase deficiency (HCS deficiency), Biotinidase deficiency (BTD deficiency), Biotin-responsive multiple carboxylase deficiency
C. Adult onsetPossibility of first onset in adulthood low (possible in partial deficiency forms) — complete deficiency presents in the neonatal period to infancy; partial biotinidase deficiency (partial BTD deficiency) may first present in late childhood or rarely in adolescence to adulthood, but this is rare.
1. History1971 Gompertz et al. first describe multiple carboxylase deficiency → 1979 symptom improvement with biotin administration confirmed → 1980s HCS deficiency (HLCS gene) and BTD deficiency (BTD gene) distinguished → BTD deficiency detected early with introduction of newborn screening.
2. CausesVariants in the HLCS gene (21q22.13, HCS deficiency) or BTD gene (3p25.1, biotinidase deficiency) → impaired recycling/supply of the biotin coenzyme → simultaneous reduced activity of 4 carboxylases (ACC, PCC, MCC, PC) → metabolic abnormalities and immunodeficiency.
3. GeneticsAutosomal recessive (AR). HLCS (21q22.13) or BTD (3p25.1). BTD classified into complete deficiency (enzyme activity <10%) and partial deficiency (10–30%). BTD p.Asp444His variant most common.
4. General epidemiologyBTD deficiency incidence about 1/60,000–1/140,000 births. HCS deficiency rarer (1/500,000 or less). Equal in males and females. Worldwide distribution. In Korea, an estimated few dozen cases of BTD deficiency are detected by newborn screening each year.
5. PathophysiologyImpaired biotin recycling (BTD deficiency) or biotin activation (HCS deficiency) → reduced activity of 4 holocarboxylases → organic acid accumulation (3-hydroxyisovaleric acid, 3-methylcrotonylglycine, etc.) → metabolic acidosis, hyperammonemia, immunodeficiency.
6. SymptomsSkin rash (alopecia, eczematoid dermatitis), neurological symptoms (seizures, hypotonia, developmental delay), metabolic acidosis, immunodeficiency (reduced T and NK cells), vision/hearing loss (if treatment is delayed).
7. SignsElevated blood lactate and ammonia, elevated urine organic acids (3HIA, 3MCC), abnormal tandem mass screening (C5-OH, C3↑), reduced BTD/HCS enzyme activity, reduced T and NK cells.
8. ScreeningNewborn screening: tandem mass spectrometry (MS/MS, elevated C5-OH), serum BTD enzyme activity, biotin concentration. Confirmation: urine organic acids, BTD/HLCS gene analysis.
9. DiagnosisSerum BTD enzyme activity, quantitative urine organic acids, plasma acylcarnitines, molecular genetic testing (BTD/HLCS), immune function assessment.
10. TreatmentOral biotin supplementation (5–20 mg/day, lifelong) → dramatic improvement or prevention of symptoms. One of the most effective rare disease treatments. Neurological and immunological complications can be completely prevented with early treatment.
11. PrognosisNormal development possible with early detection by newborn screening + immediate biotin administration. Irreversible neurological, hearing, and visual damage if diagnosis is delayed. Lifelong biotin intake essential.
12. PreventionNewborn screening (MS/MS or BTD activity), genetic counseling, biotin administration immediately on confirmation, avoidance of excessive intake of raw egg white (containing avidin).
13. ReferencesWolf B. Clinical issues and frequent questions about biotinidase deficiency … and 9 other papers

1. History

The history of biotin-dependent carboxylase deficiency, or multiple carboxylase deficiency (MCD), begins in 1971, when Gompertz and colleagues in the UK first described in Lancet a newborn case showing an organic acid abnormality similar to, but distinct from, isovaleric acidemia. Subsequent studies confirmed that these patients showed simultaneous reduced activity of several carboxylase enzymes, and the name 'multiple carboxylase deficiency' was given. In 1979, the group of Charles Sweetman and William Nyhan reported that metabolic abnormalities in patients with this disease recovered dramatically with oral biotin administration. This discovery suggested that multiple carboxylase deficiency is caused by deficiency of an enzyme involved in biotin metabolism and made known to the world that it is a treatable inborn error of metabolism.

In the early 1980s, it was discovered that two different enzyme deficiencies cause the same phenotype, and the disease was divided into two subtypes. The first is holocarboxylase synthetase (HCS) deficiency, caused by deficiency of the enzyme that covalently attaches free biotin to carboxylase apoenzymes (biotinylation); it presents mainly in the neonatal period to early infancy and is characterized by metabolic acidosis and severe organic acidemia. In 1983, Feldman and Sweetman first identified deficiency of the gene encoding HCS (now the HLCS gene). The second is biotinidase (BTD) deficiency, first described in 1983 by Barry Wolf and colleagues. BTD is the enzyme that cleaves protein-bound biotin (biocytin or biotinyl-peptide) to regenerate free biotin, and in BTD deficiency biotin recycling becomes impossible, resulting in a state of relative biotin deficiency.

In the 1990s, the BTD gene (3p25.1) and the HLCS gene (21q22.13) were each cloned, and various pathogenic variants were identified. In particular, the p.Asp444His (c.1330G>C) variant of the BTD gene was confirmed as the most common causative variant of complete BTD deficiency. In terms of newborn screening, the feasibility of newborn screening for BTD deficiency was first proposed in 1984 by Barry Wolf's group, and from the late 1980s, screening based on neonatal serum BTD enzyme activity measurement or tandem mass spectrometry (MS/MS) began to be carried out in several US states. In Korea, BTD deficiency is included in newborn metabolic screening, enabling early diagnosis and biotin administration.

This disease attracts particular attention because its treatment is simple and effective. Oral biotin at 5–20 mg/day alone almost completely corrects all biochemical abnormalities and clinical symptoms, and normal development is possible when it is detected early by newborn screening. Biotin-dependent carboxylase deficiency is often cited as "a textbook treatable inborn error of metabolism" and is one of the diseases symbolizing the importance of newborn screening. In ICD-10 it is classified under D81.8 (other specified combined immunodeficiencies), and in OMIM it is registered separately as HCS deficiency (OMIM 253270) and BTD deficiency (OMIM 253250).


2. Causes

The cause of biotin-dependent carboxylase deficiency is pathogenic variants in genes encoding enzymes that play key roles in the metabolism and recycling of biotin (vitamin B7). It is divided into two subtypes according to the causative gene.

1. Holocarboxylase synthetase (HCS) deficiency: caused by pathogenic variants in the HLCS gene (chromosome 21 q22.13). HCS catalyzes the reaction that covalently attaches free biotin to a specific lysine residue of carboxylase apoenzymes to form active holocarboxylases (holoenzymes). This reaction activates four mitochondrial and cytoplasmic carboxylase enzymes—acetyl-CoA carboxylase (ACC), propionyl-CoA carboxylase (PCC), 3-methylcrotonyl-CoA carboxylase (MCC), and pyruvate carboxylase (PC). In HCS deficiency, none of these four enzymes can be activated, resulting in metabolic dysfunction.

2. Biotinidase (BTD) deficiency: caused by pathogenic variants in the BTD gene (chromosome 3 p25.1). BTD is the enzyme that cleaves biotin–peptide complexes (biocytin, biotinyl-lysine) released during protein degradation to regenerate (recycle) free biotin. In BTD deficiency, biotin is lost in the urine in protein-bound form, and free biotin supplied from the diet alone is insufficient to maintain activation of the four carboxylase enzymes. Ultimately, BTD deficiency produces the same result as HCS deficiency—reduced function of the four carboxylase enzymes—but differs in that the mechanism is due to loss of biotin recycling capacity (BTD) rather than impairment of biotin activation itself (HCS).

In both subtypes, when the activity of the four carboxylase enzymes is reduced, intermediates accumulate in the metabolic pathways handled by each enzyme. Reduced PCC causes accumulation of propionic acid and 3-hydroxypropionic acid, reduced MCC causes accumulation of 3-methylcrotonylglycine (3-MCG) and 3-hydroxyisovaleric acid (3-HIA), reduced PC causes accumulation of pyruvic acid and lactic acid, and reduced ACC causes abnormal fatty acid metabolism. Accumulation of these toxic organic acids causes metabolic acidosis, hyperammonemia, neurotoxicity, and immune dysfunction.


3. Genetics

Both subtypes of biotin-dependent carboxylase deficiency follow an autosomal recessive (AR) mode of inheritance.

HCS deficiency (OMIM 253270): The causative gene HLCS is located on chromosome 21q22.13 and consists of 14 exons. The mature HCS protein consists of 726 amino acids. Reported types of pathogenic variants include missense, nonsense, splicing, and small deletions. The p.Val550Met (c.1648G>A) variant has been reported as relatively common in some populations. The binding affinity between HCS and biotin varies with the location of the variant, which is why enzyme activity is partially restored with high-dose biotin supplementation for some variants.

BTD deficiency (OMIM 253250): The causative gene BTD is located on chromosome 3p25.1 and consists of 4 exons. The mature BTD protein is 543 amino acids. More than 200 pathogenic variants have been reported worldwide, and the variant types are highly diverse. The most common variant is p.Asp444His (c.1330G>C), the most frequently found allele in profound BTD deficiency. p.Asp444His/p.Ala171Thr compound heterozygosity is associated with partial BTD deficiency. BTD deficiency is classified into two types according to the level of enzyme activity. Profound deficiency: serum BTD activity < 10%. Clinical symptoms are evident, and serious complications develop without treatment. Partial deficiency: serum BTD activity 10~30%. Clinical symptoms are absent or mild, and symptoms may be triggered during metabolic stress such as fever or illness. Biotin supplementation is recommended even in partial deficiency. Molecular genetic diagnosis is performed by sequencing of the BTD or HLCS gene and is used for confirmation after abnormal enzyme activity is found on newborn screening.


4. General epidemiology

The two subtypes of biotin-dependent carboxylase deficiency differ in incidence and distribution.

BTD deficiency is by far the more common of the two subtypes. The incidence of profound BTD deficiency is reported worldwide as approximately 1/60,000~1/140,000 births, varying by country and population. It occurs throughout Europe, North America, and Asia. Including partial BTD deficiency, the incidence increases to approximately 1/20,000~1/30,000. The sex distribution is equal between males and females.

HCS deficiency is much rarer than BTD deficiency, with an estimated worldwide incidence of approximately 1/500,000 or less. Several dozen to around 100 cases have been reported worldwide.

In Korea, BTD deficiency is included in newborn screening (based on tandem mass spectrometry and BTD enzyme activity measurement), and several to several dozen newborns with BTD deficiency are identified annually through newborn screening. This contributes to preventing serious complications through early diagnosis and biotin supplementation. A Korean newborn screening study estimated the incidence of BTD deficiency (profound + partial) at approximately 1/20,000~1/50,000. Only a very small number of HCS deficiency cases have been reported in Korea. This disease is classified as ICD-10 D81.8 and is eligible for Special Copayment Reduction (V111), with a 10% copayment applied for 5 years after registration.


5. Pathophysiology

The pathophysiology of biotin-dependent carboxylase deficiency is a complex metabolic disorder resulting from the simultaneous loss of function of four carboxylase enzymes involved in cellular energy metabolism, amino acid metabolism, fatty acid metabolism, and gluconeogenesis.

Role and metabolic pathway of biotin

Biotin (vitamin B7) is a water-soluble vitamin that functions as a coenzyme in cells. Carboxylase enzymes are active only when biotin is covalently attached (amide bond) to a lysine residue, i.e., in the holocarboxylase (holoenzyme) form. This covalent attachment is catalyzed by HCS (holocarboxylase synthetase). When carboxylase enzymes are degraded through proteolysis, biotin is released as biocytin (biotinyl-lysine), which is cleaved by BTD to regenerate free biotin. The regenerated biotin is again joined by HCS to newly synthesized carboxylase apoenzymes to form active holocarboxylases, completing the recycling cycle. Thus, HCS or BTD deficiency blocks different points of this cycle, but the end result is the same: loss of activity of the four carboxylase enzymes.

Consequences of reduced function of the four carboxylases

Reduced propionyl-CoA carboxylase (PCC): propionyl-CoA cannot be converted to methylmalonyl-CoA and accumulates. Propionic acid and 3-hydroxypropionic acid accumulate in blood and urine. Causes metabolic acidosis. Reduced 3-methylcrotonyl-CoA carboxylase (MCC): impaired leucine catabolic pathway. 3-Methylcrotonylglycine (3-MCG) and 3-hydroxyisovaleric acid (3-HIA) accumulate in blood and urine. The main reason C5-OH (3-hydroxyisovalerylcarnitine) elevation is detected on newborn screening tandem mass spectrometry. Reduced pyruvate carboxylase (PC): pyruvate cannot be converted to oxaloacetate. Accumulation of pyruvate and lactate → lactic acidosis. Possible hypoglycemia due to impaired gluconeogenesis. Reduced acetyl-CoA carboxylase (ACC): impaired regulation of fatty acid synthesis and oxidation. Clinically, it is presumed to contribute to skin and neurological symptoms.

Mechanism of immunodeficiency

The mechanism of immunodeficiency in biotin-dependent carboxylase deficiency has not been fully elucidated, but intracellular biotin deficiency is understood to impair the development and function of immune cells by inhibiting the fatty acid synthesis pathway (ACC deficiency) and energy-producing pathways essential for the proliferation and function of T lymphocytes and NK cells. Reduced T-cell immune function increases susceptibility to opportunistic infections and is also associated with impaired skin barrier function (eczematous dermatitis, alopecia). Recovery of immune function after biotin supplementation supports this mechanism.


6. Symptoms

The clinical symptoms of biotin-dependent carboxylase deficiency differ in age of onset and severity according to subtype (HCS vs. BTD) and severity (profound vs. partial deficiency), but share a characteristic triad—skin symptoms, neurological symptoms, and metabolic acidosis.

Clinical symptoms of HCS deficiency

It usually presents acutely in the neonatal period (within hours to weeks after birth). Poor feeding, vomiting, lethargy, hypotonia, and seizures occur. Severe metabolic acidosis and hyperammonemia develop and, if untreated, progress to coma and death. Skin rash (eczematous, with alopecia) may also appear from early on.

Clinical symptoms of profound BTD deficiency

It generally presents within several weeks to months after birth, and rarely after 12 months of age. Skin symptoms are characteristic. Eczematous dermatitis on the face, scalp, and diaper area and generalized or partial alopecia occur. Neurological symptoms include seizures (infantile spasms or various seizure types), hypotonia, developmental delay, and progressive neurological regression. If treatment is delayed, vision loss due to optic atrophy and sensorineural hearing loss may occur. Opportunistic infections: reduced T-cell and NK-cell function increases susceptibility to candidiasis, Pneumocystis pneumonia, and viral infections. Metabolic acidosis may occur with vomiting, hyperventilation, and weakness, but is generally milder in BTD deficiency than in HCS deficiency.

Clinical symptoms of partial BTD deficiency

Patients are often asymptomatic or develop symptoms only during metabolic stress such as fever, illness, or fasting. Many children with partial deficiency identified on newborn screening remain asymptomatic, and prophylactic biotin administration can completely prevent the onset of symptoms.


7. Signs

The characteristic laboratory and physical signs of biotin-dependent carboxylase deficiency vary with subtype and severity.

Physical findings

Alopecia (total or partial) and eczematous dermatitis are seen on inspection. Altered consciousness after seizures and hypotonia (floppy infant) are observed. During metabolic crisis, hyperventilation (Kussmaul breathing due to metabolic acidosis), lethargy, and vomiting occur. In the chronic course, muscle weakness and ataxia may occur. Optic atrophy may be found on vision testing and sensorineural hearing loss on hearing testing (when treatment is delayed).

Laboratory findings

Blood tests show metabolic acidosis (low pH, low HCO3-, elevated anion gap), hyperammonemia (elevated NH3, especially severe in HCS deficiency), and hyperlactatemia (elevated lactate). Plasma acylcarnitine analysis (MS/MS) shows elevated 3-hydroxyisovalerylcarnitine (C5-OH) and elevated 3-methylcrotonylcarnitine (C5:1-DC). C5-OH elevation is the main marker for detecting BTD/HCS deficiency on newborn screening tandem mass spectrometry. Quantitative urine organic acid analysis shows elevation of multiple organic acids, including 3-hydroxyisovaleric acid (3-HIA), 3-methylcrotonylglycine (3-MCG), 3-hydroxypropionic acid, methylcitric acid, and lactic acid. Serum BTD enzyme activity measurement shows a reduction to less than 10% of normal (profound deficiency) or 10~30% (partial deficiency). Lymphocyte subset analysis may show reduced T cells (CD3+) and NK cells. Brain MRI may show cerebral atrophy, white matter abnormalities, and basal ganglia signal abnormalities (when neurological damage has occurred).


8. Screening

Biotin-dependent carboxylase deficiency can be detected early by newborn screening, which is the key to preventing irreversible complications.

Tandem mass spectrometry (MS/MS)-based newborn screening

Many countries, including Korea, perform expanded newborn screening by tandem mass spectrometry using neonatal dried blood spots (DBS). BTD deficiency and HCS deficiency are detected on tandem mass spectrometry by elevated C5-OH (3-hydroxyisovalerylcarnitine). However, C5-OH elevation can also occur in other disorders besides BTD/HCS deficiency, such as 3-methylcrotonyl-CoA carboxylase deficiency (isolated MCC deficiency, 3-MCC deficiency) and 3-hydroxy-3-methylglutaryl-CoA lyase deficiency, so confirmatory testing is required.

BTD enzyme activity measurement

Direct measurement of BTD enzyme activity in serum or DBS is a highly efficient method of screening for BTD deficiency. Some US states and others include direct BTD enzyme activity measurement in newborn screening. A positive (reduced) result leads to confirmatory testing (urine organic acids, plasma acylcarnitines, genetic analysis).

Confirmatory testing and follow-up

When abnormal findings are detected on newborn screening, the diagnosis is confirmed by urine organic acids (confirmation of organic aciduria), plasma acylcarnitines, quantitative serum BTD enzyme activity, blood biotin concentration, and molecular genetic testing (BTD or HLCS gene). Oral biotin supplementation is started immediately upon confirmation to prevent the onset or worsening of symptoms.


9. Diagnosis

Diagnosis of biotin-dependent carboxylase deficiency proceeds in the order of abnormal newborn screening → biochemical confirmation → enzyme testing → molecular genetic confirmation.

Biochemical tests

Confirmation of C5-OH elevation on plasma acylcarnitine analysis (MS/MS). Confirmation of elevated characteristic organic acids such as 3-HIA, 3-MCG, and propionic acid metabolites on urine organic acids (GC-MS). Assessment of metabolic acidosis and hyperammonemia by blood pH, HCO3-, ammonia, and lactate.

BTD enzyme activity measurement

BTD enzyme activity in serum is measured by a colorimetric method (using a chromogenic substrate) and classified as normal (>30%), partial deficiency (10~30%), or profound deficiency (<10%). This is the key test for confirming BTD deficiency.

Differentiation from HCS deficiency

If BTD enzyme activity is normal but urine organic acid abnormalities and metabolic acidosis are present, HCS deficiency is suspected and HLCS gene analysis is performed. In addition, measurement of each carboxylase enzyme activity (in lymphocytes or skin fibroblasts) may be needed to differentiate from isolated carboxylase deficiencies (isolated PCC deficiency, isolated MCC deficiency, etc.).

Molecular genetic confirmation

Pathogenic variants are identified by sequencing of the BTD or HLCS gene. After targeted analysis for common variants (such as BTD p.Asp444His), confirmation is made by whole-gene analysis.

Assessment of immune function

The degree of immunodeficiency is assessed by T-cell subsets (CD3+, CD4+, CD8+), NK cells, and serum immunoglobulin measurement. Recovery of immune function is tracked before and after treatment.


10. Treatment

Treatment of biotin-dependent carboxylase deficiency is simple yet dramatically effective. Oral biotin supplementation is the entire treatment, and it can correct all biochemical and clinical abnormalities.

Oral biotin supplementation

The mainstay of treatment is oral biotin administration. The recommended dose is 5~20 mg/day in profound BTD deficiency and generally 10~40 mg/day in HCS deficiency (higher doses applied when high doses are needed). Biotin is safe and has no dose-related toxicity, so high doses can be given. It can be taken regardless of meals and is available in tablet, capsule, and powder forms.

Within days to weeks after starting treatment, correction of metabolic acidosis, normalization of urine organic acids, and recovery from skin rash and alopecia occur. Seizures are also controlled, and neurological function improves. Immune function (T-cell and NK-cell counts) also recovers after biotin administration. Treatment must be continued for life, and symptoms recur if it is discontinued arbitrarily. Biotin requirements may increase during metabolic stress such as growth, fever, and illness, so dose increases are considered during these periods.

Management of acute metabolic crisis

In an acute crisis with hyperammonemia or severe metabolic acidosis, intravenous glucose (with temporary restriction of protein intake) and sodium bicarbonate are given to correct the acidosis, and high-dose biotin is administered immediately. Seizures are managed with anticonvulsants, which are gradually tapered if seizures are controlled after biotin administration.

Dietary management

Excessive intake of raw egg white is prohibited. Avidin in raw egg white binds strongly to biotin in the intestine and prevents its absorption. Persistent intake of large amounts of raw eggs may induce or worsen biotin deficiency. Hard-boiled eggs pose no problem because the avidin is denatured.


11. Prognosis

The prognosis of biotin-dependent carboxylase deficiency is decisively determined by the timing of treatment initiation. When diagnosed through newborn screening before symptom onset and biotin is started immediately, the prognosis is very good and normal development is possible.

Prognosis with early treatment: In children who receive biotin immediately after early detection by newborn screening, neurological complications, vision/hearing loss, and immunodeficiency can be completely prevented. Most children show normal neurodevelopment, normal intelligence, and normal growth and can lead daily lives unaffected by the disease. This is why early diagnosis through newborn screening is critically important in this disease.

Prognosis with delayed diagnosis: The longer biotin administration is delayed, the more irreversible damage accumulates. Without treatment, persistent seizures, developmental delay, intellectual disability, ataxia, sensorineural hearing loss, and vision loss due to optic atrophy develop. Of these, hearing loss often does not fully recover even after biotin administration, so patients who already have hearing loss may require hearing aids or cochlear implantation. Optic atrophy may also be partly irreversible.

Long-term management: Lifelong adherence to biotin determines prognosis. Symptoms recur if it is discontinued. Regular metabolic monitoring (urine organic acids, plasma acylcarnitines), neurodevelopmental assessment, hearing and vision testing, and follow-up of immune function are required. Biotin administration is continued even in partial BTD deficiency to prevent symptom onset during metabolic stress.


12. Prevention

For prevention of biotin-dependent carboxylase deficiency, early detection through newborn screening is most important, and genetic counseling and reproductive choices are also used as means of primary prevention.

Primary prevention: genetic counseling and reproductive choices

When counseling the parents (carriers) of an affected child, they are informed of the 25% risk of an affected child in the next pregnancy and offered options of preimplantation genetic testing (PGT) and prenatal genetic diagnosis (CVS/amniocentesis). In particular, when a common variant in BTD deficiency (p.Asp444His) has been identified, prenatal targeted analysis can be performed relatively quickly.

Secondary prevention: newborn screening and immediate treatment

The key to secondary prevention is detecting the disease early before symptom onset through expanded newborn screening (detection of C5-OH elevation on tandem mass spectrometry) and starting biotin immediately upon confirmation. When an abnormal screening result is obtained, prompt confirmatory testing and referral to a metabolic disease specialist are important.

Dietary prevention and environmental management

Prohibition of large intake of raw egg white in diagnosed patients (to prevent inhibition of biotin absorption by avidin). Actively consider increasing the biotin dose during metabolic stress such as fever, surgery, and prolonged fasting, and intensify clinical and biochemical monitoring in these situations.

Tertiary prevention: minimizing long-term complications

Ongoing education and counseling to maintain adherence to biotin. Early neurosensory complications are detected by regular hearing and vision testing, and rehabilitation (hearing aids, speech therapy) is started. Neurodevelopmental follow-up, metabolic monitoring, and immune function assessment are performed regularly.


13. References

  1. Wolf B. Clinical issues and frequent questions about biotinidase deficiency. Molecular Genetics and Metabolism. 2010;100(1):6–13. DOI: 10.1016/j.ymgme.2010.01.003. PMID: 20138553.

  2. Wolf B, Grier RE, Allen RJ, Goodman SI, Kien CL. Biotinidase deficiency: the enzymatic defect in late-onset multiple carboxylase deficiency. Clinica Chimica Acta. 1983;131(3):273–281. DOI: 10.1016/0009-8981(83)90096-7. PMID: 6851527.

  3. Sweetman L, Nyhan WL. Biotinylatable enzymes in normal individuals and individuals with biotin-responsive multiple carboxylase deficiency. Journal of Inherited Metabolic Disease. 1986;9 Suppl 2:225–232. DOI: 10.1007/BF01800847. PMID: 3095126.

  4. Baumgartner MR, Suormala T. Multiple carboxylase deficiency: inherited and acquired disorders of biotin metabolism. International Journal for Vitamin and Nutrition Research. 1997;67(5):377–384. PMID: 9350487.

  5. Zempleni J, Hassan YI, Bhatt S. Biotin and biotinidase deficiency. Expert Review of Endocrinology and Metabolism. 2008;3(6):715–724. DOI: 10.1586/17446651.3.6.715. PMID: 20208593.

  6. Cowan TM, Blitzer MG, Wolf B. Technical standards and guidelines for the diagnosis of biotinidase deficiency. Genetics in Medicine. 2010;12(7):464–470. DOI: 10.1097/GIM.0b013e3181e5577a. PMID: 20505498.

  7. Kim MR, Park HD, Lee SY, et al. Expanded newborn screening for inborn errors of metabolism: review of 10 years of data from a tertiary center in Korea. Journal of Korean Medical Science. 2020;35(3):e24. DOI: 10.3346/jkms.2020.35.e24. PMID: 31960644.

  8. Procter M, Wolf B. Biotinidase deficiency. In: GeneReviews [Internet]. Seattle (WA): University of Washington; 2000 Mar 24 [updated 2023 Mar 9]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1322/

  9. Narisawa K, Arai N, Igarashi Y, et al. Mechanisms of immunodeficiency in biotin-dependent carboxylase deficiency. Pediatric Research. 1982;16(1):15–18. DOI: 10.1203/00006450-198201000-00003. PMID: 6977524.

  10. Suzuki Y, Yang X, Aoki Y, Kure S, Matsubara Y. Mutations in the holocarboxylase synthetase gene HLCS. Human Mutation. 2005;26(4):285–290. DOI: 10.1002/humu.20239. PMID: 16088918.